Allogeneic mesenchymal precursor cells (MPCs): an innovative approach to treating advanced heart failure

References

• Ziaeian B, Fonorow GC. Epidemiology and etiology of heart failure. Nat Rev Cardiol. 2016. doi:10.1038/nrcario.2016.25.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015 Jan 27;131(4):e29–322.
   PubMed Web of Science ®Google Scholar
• Gao LR, Wang ZG, Zhu ZM, et al. Effect of intracoronary transplantation of autologous bone marrow-derived mononuclear cells on outcomes of patients with refractory chronic heart failure secondary to ischemic cardiomyopathy. Am J Cardiol. 2006 Sep 1;98(5):597–602.
   PubMed Web of Science ®Google Scholar
• Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the Poseidon randomized trial. JAMA. 2012 Dec 12;308(22):2369–2379.
   PubMed Web of Science ®Google Scholar
• Patel AN, Henry TD, Quyyumi AA, et al. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. Lancet. 2016 Apr 5;387:2412–2421. pii: S0140-6736(16)30137-4.
   PubMed Web of Science ®Google Scholar
• Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. JACC. 2013;61(23):2329–2338. doi:10.1016/j.jacc.2013.02.071.
   Web of Science ®Google Scholar
• Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart generation after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012;379:895–904. doi:10.1016/S0140-6736(12)60195-0.
   PubMed Web of Science ®Google Scholar
• Henry TD, Pepine CJ, Lambert C, et al. The athena trials: autologous adipose-derived regenerative cells (ADRCs) for refractory chronic myocardial ischemia with left ventricular dysfunction. Catheter Cardiovasc Interv. 2016 May 5. doi:10.1002/ccd.26601.
   Google Scholar
• Perin EC, Borow KM, Dib N, et al. A Phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure. Circ Res. 2015 Aug 28;117(6):576–584. doi:10.1161/CIRCRESAHA.115.306332.
   PubMed Web of Science ®Google Scholar
• Pittenger MF, MacKay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–147.
   PubMed Web of Science ®Google Scholar
• Toma C, Pittenger MF, Cahill KS, et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105:93–98.
   PubMed Web of Science ®Google Scholar
• Reyes M, Dudek A, Jahagirdar B, et al. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest. 2002;109:337–346. doi:10.1172/JCI14327.
   PubMed Web of Science ®Google Scholar
• Hamamoto H, Gorman JH 3rd, Ryan LP, et al. Allogeneic mesenchymal precursor cell therapy to limit remodeling after myocardial infarction: the effect of cell dosage. Ann Thorac Surg. 2009;87:794–801. doi:10.1016/j.athoracsur.2008.11.057.
   PubMed Web of Science ®Google Scholar
• Martens TP, See F, Schuster MD, et al. Mesenchymal lineage precursor cells induce vascular network formation in ischemic myocardium. Nat Clin Pract Cardiovasc Med. 2006;3(Suppl. 1):S18–S22. doi:10.1038/ncpcardio0404.
   Google Scholar
• See F, Seki T, Psaltis PJ, et al. Therapeutic effects of human STRO-3-selected mesenchymal precursor cells and their soluble factors in experimental myocardial ischemia. J Cell Mol Med. 2011 Oct;15(10):2117–2129. doi:10.1111/j.1582-4934.2010.01241.x.
   PubMed Web of Science ®Google Scholar
• Houtgraaf JH, De Jong R, Kazemi K, et al. Intracoronary infusion of allogeneic mesenchymal precursor cells directly after experimental acute myocardial infarction reduces infarct size, abrogates adverse remodeling, and improves cardiac function. Circ Res. 2013;113:153–166. doi:10.1161/CIRCRESAHA.112.300730.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Yi G, Conditt GB, et al. Catheter based endomyocardial delivery of mesenchymal precursor cells using 3D echo guidance improves cardiac function in a chronic myocardial injury ovine model. Cell Transplant. 2013;22(12):2299–2309. doi:10.3727/096368912X658016.
   PubMed Web of Science ®Google Scholar
• Psaltis PJ, Carbone A, Nelson AJ, et al. Worthley, reparative effects of allogeneic mesenchymal precursor cells delivered transendocardially in experimental nonischemic cardiomyopathy. JACC Cardiovasc Interv. 2010 Sep;3(9):974–983. doi:10.1016/j.jcin.2010.05.016.
   PubMed Web of Science ®Google Scholar
• Ascheim DD, Gelijns AC, Goldstein D, et al. Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. Circulation. 2014 Jun 3;129(22):2287–2296. doi:10.1161/CIRCULATIONAHA.113.007412.
   PubMed Web of Science ®Google Scholar
• Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res. 2013 Aug 30;113(6):810–834. doi:10.1161/CIRCRESAHA.113.300219.
   PubMed Web of Science ®Google Scholar
• Schuleri KH, Feigenbaum GS, Centola M, et al. Autologuous mesenchymal stem cells produce reverse remodeling in chronic ischemic cardiomyopathy. Eur Heart J. 2009;30:2722–2732. doi:10.1093/eurheartj/ehp265.
   PubMed Web of Science ®Google Scholar
• Silva GV, Litovsky S, Assad JA, et al. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation. 2005;111:150–156. doi:10.1161/01.CIR.0000151812.86142.45.
   PubMed Web of Science ®Google Scholar
• Nagaya N, Kangawa K, Itoh T, et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation. 2005;112:1128–1135. doi:10.1161/CIRCULATIONAHA.104.500447.
   PubMed Web of Science ®Google Scholar
• Liu JF, Wang BW, Hung HF, et al. Human mesenchymal stem cells improve myocardial performance in a splenectomized rat model of chronic myocardial infarction. J Formos Med Assoc. 2008;107:165–174. doi:10.1016/S0929-6646(08)60130-8.
   PubMed Web of Science ®Google Scholar
• Li L, Zhang S, Zhang Y, et al. Paracrine action mediate the antifibrotic effect of transplanted mesenchymal stem cells in a rat model of global heart failure. Mol Biol Rep. 2009;36:725–731. doi:10.1007/s11033-008-9235-2.
   PubMed Web of Science ®Google Scholar
• Mazo M, Gavira JJ, Abizanda G, et al. Transplantation of mesenchymal stem cells exerts a greater long-term effect than bone marrow mononuclear cells in a chronic myocardial infarction model in rat. Cell Transplant. 2010;19:313–328. doi:10.3727/096368909X480323.
   PubMed Web of Science ®Google Scholar
• Freyman T, Polin G, Osman H, et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J. 2006 May;27(9):1114–1122. doi:10.1093/eurheartj/ehi818.
   PubMed Web of Science ®Google Scholar
• Perin EC, Silva GV, Assad JA, et al. Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction. J Mol Cell Cardiol. 2008 Mar;44(3):486–495. doi:10.1016/j.yjmcc.2007.09.012.
   PubMed Web of Science ®Google Scholar
• Psaltis PJ, Carbone A, Leong DP, et al. Assessment of myocardial fibrosis by endoventricular electromechanical mapping in experimental nonischemic cardiomyopathy. Int J Cardiovasc Imaging. 2011 Jan;27(1):25–37. doi:10.1007/s10554-010-9657-5.
   PubMed Web of Science ®Google Scholar
• Macia E, Boyden PA. Stem cell therapy is proarrhythmic. Circulation. 2009;119:1814–1823. doi:10.1161/CIRCULATIONAHA.108.779900.
   PubMed Web of Science ®Google Scholar
• Fisher SA, Doree C, Mathur A, et al. Meta-analysis of cell therapy trials for patients with heart failure. Circ Res. 2015;116:1361–1377. doi:10.1161/CIRCRESAHA.116.304386.
   PubMed Web of Science ®Google Scholar